Lexaria Bioscience Corp.
156 Valleyview Road
Kelowna
British Columbia
V1X3M4
United States
Tel: 250-765-6424
Website: http://www.lexariaenergy.com
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.YEAR FOUNDED:
2004
LEADERSHIP:
CEO: Chris Bunka
FOLLOW LEXARIA BIOSCIENCE:
Tweets by Lexaria Bioscience
100 articles about Lexaria Bioscience Corp.
-
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
3/14/2024
Lexaria Bioscience Corp. announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately.
-
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
3/7/2024
Lexaria Bioscience Corp. announces it has hired a contract research organization to perform the Company's second DehydraTECH-powered glucagon-like peptide 1 human pilot study #2 (the "Study").
-
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
3/5/2024
Lexaria Bioscience Corp. announces details of an 8-week animal study WEIGHT-A24-1 (the "Study") to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 ("GLP-1") drugs and DehydraTECH-processed cannabidiol, alone and in combination.
-
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2/15/2024
Lexaria Bioscience Corp. announced that it has entered into definitive agreements for the purchase and sale of 1,558,443 shares of common stock at a purchase price of $2.31 per share in a registered direct offering priced at-the-market under Nasdaq rules.
-
Lexaria Releases Annual Letter from the CEO - January 24, 2024
1/24/2024
Lexaria Bioscience Corp. is pleased to provide this annual letter from CEO Chris Bunka as a strategic update to all stakeholders.
-
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
1/16/2024
Lexaria Bioscience Corp. announces a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with the global pharmaceutical companies.
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
1/11/2024
Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.”
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
1/9/2024
Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
-
Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide
1/4/2024
Lexaria Bioscience Corp. (NASDAQ:LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive final results from its recently completed human Pilot Study #1 (the "Study") evaluating DehydraTECHTM technology for the oral delivery of the glucagon-like peptide-1 ("GLP-1") drug semaglutide available commercially in the branded product Rybelsus®.
-
Lexaria's Investigational New Drug Application Filing Update
12/7/2023
Lexaria Bioscience Corp. announces that the Company's anticipated submission of an Investigational New Drug application with the U.S. Food and Drug Administration for its planned U.S. Phase 1b Hypertension Clinical Trial is expected to be filed within approximately 45 days.
-
Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study
11/27/2023
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive interim results from a human pilot study (the "Study") currently underway evaluating DehydraTECHTM technology for the oral delivery of the glucagon-like peptide-1 ("GLP-1") drug semaglutide available commercially in the branded product Rybelsus®.
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
11/1/2023
NetworkNewsAudio – Lexaria Bioscience Corp. announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Even Better?”.
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
10/31/2023
Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
-
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
9/29/2023
Lexaria Bioscience Corp. announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to purchase 1,618,330 shares of common stock in a registered direct offering.
-
Lexaria Provides Update on Investigational New Drug Application Progress
8/30/2023
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this update on the status of the Company's anticipated submission of an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its planned U.S. Phase 1b Hypertension Clinical Trial designated as HYPER-H23-1.
-
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
7/28/2023
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned subsidiary under the name Lexaria Nutraceutical Corp. ("LEXX Nutra").
-
Lexaria Appoints New Chief Financial Officer - June 12, 2023
6/12/2023
Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the appointment of a new Chief Financial Officer.
-
Lexaria is Receiving Four New Patents
4/20/2023
Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces that it has received notifications of four new patents either awarded or allowed.
-
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
2/21/2023
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce additional findings from its human clinical study HYPER-H21-4 ("the Study") demonstrating a potentially novel mechanism of action of its patented DehydraTECH-processed cannabidiol ("CBD") capsule formulation in reducing blood pressure ("BP").
-
Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
12/21/2022
Lexaria Bioscience Corp. is pleased to announce it has demonstrated superior cannabidiol ("CBD") blood absorption levels from its patented DehydraTECH-CBD™ relative to those of published, pharmaceutical-grade CBD industry comparators in its recently completed, multi-week human clinical hypertension study HYPER-H21-4.